SELLAS Life Sciences is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.

The Company’s lead product candidate, licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute (NCI) as the number 1 target for immunotherapy. Traditional approaches have not been able to address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies. The company has a close working relationship with MSKCC, who is also a shareholder.

The Company plans to initiate a pivotal Phase III study in H2:17 in acute myeloid leukemia (AML) as well as malignant pleural mesothelioma (MPM) by EOY:17/H1:18. SELLAS is currently conducting Phase I and Phase II studies in multiple myeloma (MM) and ovarian cancer (combination with BMS’s nivolumab (Opdivo®)) and will advance additional studies into the clinic. Phase II data in AML and MPM have shown positive safety and survival trends, with median overall survival (OS) in AML of 67.6 months vs. ~12-15 months for best standard treatment (in patients of all ages) and median OS in MPM of 24.8 months vs. 16.6 months in the control arm. Further recent data in multiple myeloma has shown an 88% overall survival rate after 18 months in patients with high-risk cytogenetics following stem cell transplantation. The US FDA granted orphan designations and fast track designations for SELLAS' WT1 therapy, galinpepimut-S, for AML and MPM and the European EMA granted orphan designation for AML and MPM.

Galinpepimut-S has the potential to complement currently available therapies by destroying residual tumor cells of cancers in remission and providing ongoing immune surveillance to avoid or significantly delay tumor recurrence. Its use in this setting is aided by an attractive safety profile not found in standard of care therapies.

SELLAS was founded in 2012 and is headquarted in Hamilton, Bermuda, with additional offices in New York.



Angelos M. Stergiou, MD, ScD h.c. , Chief Executive Officer & Vice Chairman of the Board

Angelos M. Stergiou, MD is Chief Executive Officer and Vice Chairman of SELLAS Life Sciences Group. He brings more than 15 years of experience in the global pharmaceutical industry, leading companies and people from scientific research through regulatory approval to develop medicines that address compelling medical needs.

Prior to joining SELLAS, Dr. Stergiou held positions of increasing responsibility in the United States and Europe in pharma and biotechnology companies including PAION AG, Accentia Biopharmaceuticals, BioVest International, Anavex Life Sciences as well as Clinical Research Organizations. Dr. Stergiou has held specific roles ranging from Medical Director, Head of Clinical Research, Vice President and President, Product Development, with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC) as well as Chief Medical Officer and Chief Operating Officer. He also founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences, and performed work for big pharma.

Dr. Stergiou is a Fellow of the Royal Society of Medicine (UK), active member of the World Medical Association, the American Academy of Pharmaceutical Physicians and Investigators, the Association of Clinical Research Professionals, International Society for Pharmacoeconomics and Outcomes Research, amongst others Dr. Stergiou holds a Doctor of Medicine degree and is a graduate of Kentucky Wesleyan (USA) and has done elective clinical work in interventional cardiology and surgery at the General Hospital Hagen and the University of Cologne. He is a frequent speaker and lecturer at renowned Universities in the US and Europe and has experience with all major global health authorities.


William Pollett, ACA, CFA , Chief Financial Officer

William (Bill) Pollett is the Chief Financial Officer of SELLAS Life Sciences Group. Mr. Pollett brings over 25 years of financial management and capital markets experience to the Company. Prior to joining SELLAS in September 2016, Mr. Pollett was President and Chief Executive Officer of Blue Capital, the wholly-owned asset management company of Montpelier Reinsurance Holdings Ltd (“Montpelier”; NYSE: “MRH”). In that role he raised nearly one billion dollars of capital in various private and public investment vehicles, investing primarily in catastrophe reinsurance products, including the successful Initial Public Offering in 2012 of Blue Capital Global Reinsurance Holdings Ltd on the London Stock Exchange (LSE: “BCGR”), and Blue Capital Reinsurance Holdings Ltd in 2013 on the New York Stock Exchange (NYSE: “BCRH”). Mr. Pollett concurrently served as President, Chief Executive Officer and a Director of BCRH, President, Chief Executive Officer of Blue Water Re, a licensed reinsurance company, and Blue Capital Management Ltd., a registered investment advisor, and as Chief Corporate Development and Strategy Officer and Treasurer of Montpelier. Mr. Pollett resigned from all positions at Blue Capital and Montpelier following its acquisition by Endurance Specialty Holdings Ltd. (NYSE: “ENH”) in 2015.

Prior to joining Montpelier in 2006, Mr. Pollett worked for five years with the ACE Group (now Chubb), initially as Chief Financial Officer of ACE Tempest Re, the reinsurance subsidiary and latterly as Senior Vice President and Senior Financial Analyst of ACE Limited, the holding company. Prior to the ACE Group, Mr. Pollett worked for the OIL Group of Companies for seven years in a number of roles including Controller and Treasurer and, prior to that, was an auditor with Coopers & Lybrand in London and Bermuda for five years. He holds a Bachelor of Commerce (Honours) degree from Edinburgh University, and is a Chartered Financial Analyst (CFA Institute) and Chartered Accountant (ICAEW).


Nicholas J. Sarlis, MD, PhD, FACP , Chief Medical Officer & Senior VP

Dr. Nicholas J. (Nick) Sarlis is an experienced clinician and recognized expert in the global pharmaceutical market with a focus in Oncology and Hematology. He has a deep understanding of the status of and emerging trends in clinical & translational research and patient care in Oncology at a global scale and specialized knowledge in medical affairs and late clinical development (US and EU).

As former Vice President and Head of Global Medical Affairs at Incyte Corporation, Dr. Sarlis led a global team supporting targeted and immuno-oncology pipeline agents. He led the integrated medical affairs plan to support the late clinical development of the innovative immuno-enhancer epacadostat and the original indoleamine 2,3-dioxygenase type-1 (IDO1) inhibitor. Dr. Sarlis and his team supported the highly successful successive launches of ruxolitinib [Jakafi®] – the original Janus kinase (JAK) inhibitor- in myelofibrosis and polycythemia vera. Prior to his time at Incyte, Dr. Sarlis held senior positions at Sanofi Aventis having led medical teams for launching key oncology and cancer supportive care products (US & EU). He received his medical degree and doctorate from the University of Athens, and a Ph.D. in Molecular Biology/ Neuroendocrinology from the Imperial College in London. Sarlis is Board Certified by the American Board of Internal Medicine, and previously served as senior faculty at the National Institutes of Health and Associate Professor at MD Anderson Cancer Center.

Dr. Sarlis has published more than 130 articles (peer-reviewed papers, textbook chapters and monographs). He has received numerous awards, being most recently nominated as the recipient of the 2016 Annual Award by Cancer Research and Treatment Fund (CR&T). He is a Fellow of the American College of Physicians (FACP), the American College of Endocrinology (FACE), the Royal Society of Medicine (UK; FRSM), and the Molecular Medicine Society (FMMS).


Jonathan Eckard, Ph.D. , Chief Business & Strategy Officer

Jonathan Eckard has over 10 years of Wall Street experience following the biotechnology sector, bringing to SELLAS both important industry insights and an understanding of the healthcare equity markets. During his time on Wall Street, he received several accolades including Institutional Investor “Best up-and-comer” and “Rising Star” in Biotechnology research.

Most recently Jonathan was a Director and Senior Equity Research Analyst at Barclays Capital Markets in New York covering the small- and mid-cap Biotechnology sector. Prior to joining Barclays, Jonathan worked for three years at Citi where he covered the Biotechnology and Specialty Pharmaceuticals sectors. Previously he spent five years at Leerink Swann and two years at HSBC working in Biotechnology equity research.

Prior to his career in financial services, Jonathan was in academia conducting cancer research and teaching at the NYU School of Medicine. He earned a BS in Biochemistry from Ohio University, an MS in Toxicology and a PhD in Toxicology and Carcinogenesis from NYU School of Medicine.


Martin G. Baum , Chief Operating Officer

Martin G. Baum brings to SELLAS over 25 years’ experience building and leading global biopharmaceutical companies through continued growth and has held senior executive positions in commercialization, market access, sales and operations.

Most recently, Mr. Baum served as founding partner and Managing Director of Komedica, a healthcare consulting firm. Previously, he founded and served as President and Chief Executive Officer of Vestiq Pharmaceuticals, which was sold to a holding of Praelia Pharmaceuticals Inc. in 2013. Prior to this, Mr. Baum was the President and Chief Executive Officer of Turnberry Development and previously was Founder and Chief Executive Officer of TEAMM Pharma, a specialty pain company that he sold to Accentia Biopharma and took public in 2005. Prior to this, he held the position of Senior Vice President, Commercial Operations at DJ Pharmaceuticals, where he helped achieve profitability within two years and sold the Company to Biovail Corporation. He also was a founding member and served as Senior Vice President of Operations and BD at Skye Pharma PLC, an international company focused on generics and novel drug delivery technologies.

He began his career with Merrell Dow Pharmaceuticals and GlaxoSmithKline Pharmaceuticals. Mr. Baum is a founding member of Health Scape Data and sits on the board of Inno BioPharma, an early stage oncology development company spun out of the University of Iowa. Mr. Baum graduated from the University of Toledo, with BS degrees in Human Life Sciences and Business Administration.


Gregory M. Torre, PhD, JD , CRO & Senior VP, Technical Operations

Gregory M. Torre, PhD, JD, is a scientist-attorney with 35 years of hands-on international executive leadership experience in the pharmaceutical and biotech industries.

Prior to joining SELLAS, Dr. Torre served as Vice President, Worldwide Regulatory Strategy – Global Established Products at Pfizer, Inc. Prior to this, he was Vice President of Drug Development at Elusys Therapeutics Inc., and served as Pharmaceutical Science and Legal Consultant at Axiom Law/The Torre Group. Previously, Dr. Torre held senior positions at Alvogen, including Vice President, Regulatory Affairs and Quality; Chief Compliance Officer, and Intellectual Property and Regulatory Council. Prior to joining Alvogen, Dr. Torre was the Senior Vice President for Regulatory Affairs, Quality and Technical Operations at NPS Pharmaceuticals, and he also held positions at MannKind. Prior to this, at Biovest, he was instrumental in developing FDA-acceptable surrogate markers and endpoints for an autologous vaccine to treat non-Hodgkin lymphoma. During his career, Dr. Torre also held leadership positions at Bristol-Myers Squibb, Sanofi, Sankyo and Novartis.

Dr. Torre received his J.D. from Brooklyn Law School, and he is a member of the Bar in the State of New Jersey, the District of Columbia and the United States Supreme Court. He received his BS in Pharmacy from St. John’s University, College of Pharmacy and Allied Health Professions and is a registered Pharmacist in the State of New York. He was also awarded an MS in Pharmacology/Toxicology and a PhD in Pharmacology/Toxicology from the same institution.


Laura M. Katz, MPH , VP, Clinical Operations & Biostatistics

Laura M. Katz, MPH, is the Head of Clinical Operations & Biostatistics at SELLAS Life Sciences Group. Laura brings extensive experience in clinical development and clinical and statistical consulting in the pharmaceutical and biotechnology industries.

Prior to joining SELLAS, Laura served as Senior Clinical Project Manager/Senior International Manager at Novo Nordisk in the biopharmaceutical group, where held leading roles on global teams with responsibility for international management of clinical trials in Phases II to IV. Laura was also responsible for the oversight of clinical activities across multiple portfolios in pediatric and adult populations, and directed trials out of both the US and European offices. Previously, Laura served as Associate Director of Biostatistics and Clinical Project Management at Accentia Biopharmaceuticals and as a Consultant at Analytica International and Columbia University.

Laura holds a Master of Public Health in Epidemiology and Biostatistics from Columbia University and a Bachelor of Science in Biostatistics from Cornell University. She has published in prominent journals including the American Journal of Hematology; the American Journal of Public Health; the Journal of the American Academy of Child and Adolescent Psychiatry; and the Annals of Allergy, Asthma, and Immunology.


David Moser, JD , VP, Legal Affairs

David Moser is VP of Legal Affairs at SELLAS Life Sciences Group. Mr. Moser has extensive experience in the biopharmaceutical industry spanning all fields of legal involvement. Prior to SELLAS, Mr. Moser served as Director of Legal Affairs and Secretary of BioVest International, Inc. a subsidiary of Accentia Biopharmaceuticals, where he was responsible for the SEC reporting management for two public biotech companies, documentation and closing of multiple rounds of Private Placement financing, in-house legal oversight of all agreements, S-1 and S-3 drafting, IPO closing, insider trading compliance manager, negotiation, drafting and administration of contracts and more. He also has previously worked in brokerage, civil litigation and general corporate law.

Mr. Moser received a BA degree in Political Science & Economics from Columbia University, New York, and a JD degree from Harvard Law School, Cambridge, MA.

Board of Directors


Luis Palacios, MBA , Chairman of the Board

Luis Palacios is Chief Executive Officer of Elystone Capital SA, a boutique wealth management firm that he founded in 2002. Previously, Mr. Palacios was a private banker at Bank Morgan Stanley AG, establishing the firm’s wealth management practice in Geneva. Prior to this, he was a private banker at Hentsch & Cie. Mr. Palacios received his bachelor’s degree in industrial engineering from the Universidad Catolica Argentina, Buenos Aires and his MBA degree from INSEAD, Fontainebleau, France.


Angelos M. Stergiou, MD, ScD h.c. , Chief Executive Officer & Vice Chairman of the Board

Angelos M. Stergiou, MD brings more than 15 years of experience in the global pharmaceutical industry, leading companies and people from scientific research through regulatory approval to develop medicines that address compelling medical needs. Prior to joining SELLAS, Dr. Stergiou held positions of increasing responsibility in the United States and Europe in pharma and biotechnology companies including PAION AG, Accentia Biopharmaceuticals, BioVest International, Anavex Life Sciences as well as Clinical Research Organizations. Dr. Stergiou has held specific roles ranging from Medical Director, Head of Clinical Research, Vice President and President, Product Development, with responsibility for medical affairs, clinical research and development, pharmacovigilance and clinical operations, among other functions. Dr. Stergiou is a Fellow of the Royal Society of Medicine (UK) and holds a Doctor of Medicine degree and is a graduate of Kentucky Wesleyan (USA).


Miltos K. Sugiultzoglu, MD , Member

Dr. Miltos K. Sugiultzoglu, MD, is an accomplished corporate development professional with a broad understanding of all aspects of clinical development and medical affairs. Dr. Sugiultzoglu has worked in the pharmaceutical industry as consultant for private companies across various disciplines.  He holds a degree in Biomedical Engineering as well as a Medical Degree from Boston University. Dr. Sugiultzoglu completed his Residency in Neurosurgery at Cornell Medical Center – Memorial Sloan Kettering Cancer Center in New York, and has done extensive research in Boston and Rockefeller University.


Gregory Raskin, MD , Member

Gregory Raskin, MD is Vice President, Technology Development at Memorial Sloan Kettering Cancer Center (MSK), where he leads technology transfer, commercialization, and business development at the world’s oldest and largest private cancer center. Prior to joining MSKCC in 2012, Dr. Raskin was a Vice President at Alliance Bernstein LP, where he led healthcare and life sciences investing for the firm’s $200 million venture capital fund. Dr. Raskin’s previous experience includes serving as a biotech analyst at Baker Brothers Investments and as a management consultant at McKinsey & Company, where he worked mainly with pharmaceutical and biotech companies.

Dr. Raskin received both his bachelor’s degree in molecular biophysics and biochemistry and his medical degree from Yale University. Dr. Raskin also was a resident physician in the internal medicine department of New York University Medical Center.

Scientific Advisory Board

David A.Scheinberg

David A.Scheinberg,MD, PHD

Jedd D. Wolchok

Jedd D. Wolchok,MD, PhD

Jeffrey Weber

Jeffrey Weber, MD, PHD


Alexander M.M. Eggermont, MD, PHD

Larry W. Kwak

Larry W. Kwak,MD, PHD

Javier Pinilla-Ibarz

Javier Pinilla-Ibarz, MD, PHD

Sattva Neelapu

Sattva Neelapu,MD, PHD

Guenther Koehne

Guenther Koehne,MD, PhD

David A. Scheinberg, MD, PhD, is Chair of the Center for Experimental Therapeutics and the Vincent Astor Chair at Memorial Sloan Kettering Cancer Center (MSKCC), where he treats patients with leukemia. Dr. Scheinberg also serves as Chair of the Molecular Pharmacology Program at the Sloan Kettering Institute. He is a professor of medicine and of pharmacology at Weill Cornell Medical College and a founder and director of the Therapeutics Discovery Institute, a joint effort of Weill Cornell, the Rockefeller University, and MSKCC.

Dr. Scheinberg’s research is focused on discovering and developing novel, specific immunotherapeutic agents and to understand their mechanisms of action as well as the mechanisms of resistance to them. Eight different therapeutic agents developed in Dr. Scheinberg’s laboratory have reached human clinical trials. His laboratory is also investigating cellular resistance mechanisms to these agents.

Dr. Scheinberg received his bachelor’s degree from Cornell University and his MD and PhD in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine.

Jedd D. Wolchok, MD, PhD is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSKCC); an associate director of the Ludwig Center for Cancer Immunotherapy at MSKCC, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSKCC. He is director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. He is also the co-director of the Swim Across America laboratory at MSKCC, one of the foremost immunotherapy and melanoma research groups in the country.

His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma.

Dr. Wolchok has authored numerous articles concerning DNA vaccines, cytokine biology, and clinical care of melanoma and co-authored two chapters in the definitive textbook, Cutaneous Melanoma. Dr. Wolchok is also co-editor of the journal Cytotherapy.

Dr. Jeffrey Weber, a specialist in cancer immunotherapy, is currently deputy director of the Perlmutter Cancer Center and the co-director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is principal investigator on several ongoing studies funded by the National Cancer Institute (NCI) as well as industry, including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He earned his PhD in molecular biology from Rockefeller University (NY) in 1979 and his MD from New York University in 1980. Dr. Weber sat on the NCI’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He has published more than 150 articles in the top peer-reviewed journals in his field.

Alexander M.M. Eggermont is currently the Director General of Institut Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, as well as Professor of Oncology at the University Paris-Sud. He is the past Professor of Surgical Oncology and current Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam. He holds the honorary Chair of Surgical Oncology at the Catholic University of Louvain, Belgium. Prof. Eggermont is a past President of the European Cancer Organisation and European Organisation for Research and Treatment of Cancer (EORTC) and past Chair of the EORTC Melanoma Group. He is the current President of the European Academy of Cancer Sciences, the chairman of Cancer Core Europe and Chair of the International Jury for Comprehensive Cancer Centre Program in Germany, as well as board member of the European Society for Medical Oncology. He obtained his MD at the University of Amsterdam and PhD in tumor immunology at the Erasmus University in Rotterdam, both in the Netherlands, and was a Fellow of the NCI Surgery Branch in Bethesda, MD, USA. He has published more than 800 peer reviewed publications.

Larry W. Kwak, MD, PhD is Cancer Center Associate Director, Translational Research & Developmental Therapeutics for the City of Hope National Medical Center, Director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute, and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine. From 2004 to 2014, Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, where he also held the Jane and John Justin Distinguished Chair in Leukemia Research. Prior to his role at M.D. Anderson, Dr. Kwak served as Head of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute for 12 years. His laboratory at the NCI was credited with the bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies. In 2010, Kwak was named to TIME Magazine’s TIME100 as one of the world’s 100 most influential people for his 20-year commitment to the science of cancer vaccines, specifically a personalized therapy for follicular lymphoma. Dr. Kwak received his medical degree from Northwestern University Medical School and earned his Ph.D. in tumor cell biology there in 1984. He also completed a residency in internal medicine and a fellowship in medical oncology at Stanford University Medical Center in California.

Dr. Javier Pinilla-Ibarz has a long track record of successfully applying immunology clinical and translational approaches to the treatment of leukemias and myelodysplastic syndromes. He is currently an associate member of the malignant hematology and immunology program and Director of Immunotherapy for Malignant Hematology at the H. Lee Moffitt Cancer Center, as well as an associate professor in the Department of Oncologic Sciences, University of South Florida College of Medicine, both in Tampa, FL. Dr. Pinilla-Ibarz received his MD and then PhD degrees from the University of Zaragoza, Spain. He then completed a research fellowship in Immunology at the Memorial Sloan-Kettering Cancer Center, as well as a Hematology and Oncology training at the same Institution. Dr. Pinilla-Ibarz has published more than 100 articles in the top peer-reviewed journals in his field.

Sattva Neelapu, MD, PhD, serves as an Associate Professor of Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas M.D. Anderson Cancer Center.

Dr. Neelapu laboratory is focused on characterization of immune-regulatory mechanisms in the tumor microenvironment in patients with lymphoma and development of novel therapeutic strategies for patients with lymphoma. His research is supported and recognized by numerous awards from national and international organizations including the National Institutes of Health, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, Doris Duke Charitable Foundation, and Leukemia and Lymphoma Society.

Dr. Neelapu obtained his medical degree in India and subsequently moved to the United States of America where he completed residency in Internal Medicine at Coney Island Hospital, Brooklyn, New York, and clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Guenther Koehne, MD, PhD is an Attending Physician of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center (MSKCC). Prior to assuming this role in 2014, he held the position of Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at MSKCC from 2010. He was Associate Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service from 2007 to 2014.

He is Associate Professor of Medicine of the Weill Cornell Medical College of Cornell University. He leads research at the BMT Department/Immunology Program to develop adoptive immunotherapeutic strategies for post-transplant blood disorders. Dr. Koehne has particular expertise in the creation and monitoring of antigen-specific T cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients.

Dr. Koehne graduated with his Medical Degree in 1991 from the Medical University of Hamburg in Germany, and received his PhD from the same institution in 1996. He completed residencies at the Medical University of Hamburg General Hospital and Rush University Medical Center, before undertaking his fellowship training at MSKCC and Weill Cornell Medical College. He has been at MSKCC since 1996. Dr. Koehne is board certified in both Internal Medicine and Medical Oncology, and keeps up to date with the latest advances in his field by maintaining a professional membership with the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation.